Abstract
Purpose :
The objective of this study was to investigate the effectiveness of topical spironolactone in treating MGD, a major component of dry eye syndrome.
Methods :
Twenty patients with moderate to severe meibomian gland disease were included in this study. Patients who were taking glaucoma medications, steroid eye drops and other lipid-altering eye drops were excluded from the study. Subjective global dry eye assessment, keratitis and conjunctival staining, anterior blepharitis grade, gland obstruction grade, meibum turbidity grade, meibum viscosity grade, zone A posterior lid margin grade, best corrected vision, and Schirmer‘s score were compared in a pre-post study. Follow-up times ranged from 1 to 7 weeks, with an average of approximately 3 weeks. Statistical analysis was performed using STATA 13 by fitting scored data to a non-parametric model
Results :
Patients with moderate to severe MGD had improved self-reported global assessment scores (p = 0.010), turbidity score (p = 0.001), and Zone A scores (p = 0.025) after treatment with topical ophthalmic suspensions of spironolactone.
Conclusions :
MGD patients reported improved dry eye symptoms after a week of using spironolactone suspension. The quality of expressed meibum secretions of patients showed improved clarity and viscosity post-treatment. Inflammation decreased at the avascular region posterior to the posterior lid margin post-treatment.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.